Spanish flag Español
Medicina Interna Basada en la Evidencia

Portal para médicos

ASH (2021): prevención y tratamiento de TVP y EP en neoplasias malignas

19.12.2022
Título original: Zaburzenia hemostazy – postępy 2021/2022
Autor: Jerzy Windyga (MD, PhD)
En 2021 un equipo multidisciplinar de expertos, formado bajo el auspicio de la American Society of Hematology (ASH) en cooperación con McMaster University GRADE Center (Hamilton, Ontario, Canadá) publicó las guías relativas a la prevención y tratamiento de TVP y EP en enfermos con neoplasia concomitante.20 Remito a los lectores al comentario detallado de este documento, que puede consultarse aquí. (…)

Bibliografía:
  1. Greinacher A., Thiele T., Warkentin T.E. y cols., Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination, N. Engl. J. Med., 2021; 384: 2092-2101
  2. Schultz N.H., Sorvoll I.H., Michelsen A.E. y cols., Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination, N. Engl. J. Med., 2021; 384: 2124-2130
  3. Scully M., Singh D., Lown R. y cols., Pathologic antibodies to platelet factor 4 after ChAdOx1 nCoV-19 vaccination, N. Engl. J. Med., 2021; 384: 2202-2211
  4. Muir K.L., Kallam A., Koepsell S.A., Gundabolu K., Thrombotic thrombocytopenia after Ad26.COV2.S vaccination, N. Engl. J. Med., 2021; 384: 1964-1965
  5. Windyga J., Zaburzenia hemostazy – postepy 2020/2021, Med. Prakt., 2021; 9: 62-69
  6. Makris M., Pavord S., Lester W. y cols., Vaccine-induced immune thrombocytopenia and thrombosis (VITT), Res. Pract. Thromb. Haemost., 2021; 5: e12 529
  7. Pavord S., Scully M., Hunt B.J. y cols., Clinical features of vaccineinduced immune thrombocytopenia and thrombosis, N. Engl. J. Med., 2021; 385: 1680-1689
  8. Medicines and Healthcare products Regulations Agency: Coronavirus vaccine – summary of Yellow Card, https://tinyurl.com/uwx6jpjh (acceso 26.07.2021)
  9. Arepally G.M., Ortel T.L., Vaccine-induced immune thrombotic thrombocytopenia: what we know and do not know, Blood, 2021; 138: 293-298
  10. See I., Su J.R., Lale A. y cols., US case reports of cerebral venous sinus thrombosis with thrombocytopenia after Ad26.COV2.S vaccination, March 2 to April 21, 2021, JAMA, 2021; 325: 2448-2456
  11. Klok F.A., Pai M., Huisman M.V., Makris M., Vaccine-induced immune thrombotic thrombocytopenia, Lancet Haematol., 2022; 9: e73-e80
  12. Pavord S., Hunt B.J., Horner D. y cols.; Guideline Committee: Vaccine induced immune thrombocytopenia and thrombosis: summary of NICE guidance, BMJ, 2021; doi: 10.1136/bmj.n2195
  13. Warkentin T.E., Greinacher A., Spontaneous HIT syndrome: knee replacement, infection, and parallels with vaccine-induced immune thrombotic thrombocytopenia, Thromb. Res., 2021; 204: 40-51
  14. Rollin J., Pouplard C., Gruel Y., Risk factors for heparin-induced thrombocytopenia: focus on Fcγ receptors, Thromb. Haemost., 2016; 116: 799-805
  15. Perdomo J., Leung H.H.L., Ahmadi Z. y cols., Neutrophil activation and NETosis are the major drivers of thrombosis in heparin-induced thrombocytopenia, Nat. Commun., 2019; 10: 1322
  16. Khandelwal S., Barnes A., Rauova L. y cols., Complement mediates binding and procoagulant effects of ultralarge HIT immune complexes, Blood, 2021, 138: 2106-2116
  17. Schönborn L., Thiele T., Kaderali L. y cols., Most anti-PF4 antibodies in vaccine-induced immune thrombotic thrombocytopenia are transient, Blood, 2022, 139: 1903-1907
  18. Schönborn L., Thiele T., Kaderali L., Greinacher A., Decline in pathogenic antibodies over time in VITT, N. Engl. J. Med., 2021; 385: 1815-1816
  19. Lacy J., Pavord S., Brown K.E., VITT and second doses of Covid-19 vaccine, N. Engl. J. Med., 2022; doi: 10.1056/NEJMc2 118 507
  20. Lyman G.H., Carrier M., Ay C. y cols., American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer, Blood Adv., 2021; 5: 927-974
  21. Windyga J., Profilaktyka i leczenie zylnej choroby zakrzepowo-zatorowej u chorych na nowotwór zlosliwy. Omówienie wytycznych American Society of Hematology 2021, Med. Prakt., 2021; 7-8: 8-15
  22. Zheng X.L., Vesely S.K., Cataland S.R. y cols., ISTH guidelines for the diagnosis of thrombotic thrombocytopenic purpura, J. Thromb. Haemost., 2020; 18: 2486-2495
  23. Zheng X.L., Vesely S.K. Cataland S.R. y cols., ISTH guidelines for treatment of thrombotic thrombocytopenic purpura, J. Thromb. Haemost., 2020; 18: 2496-2502
  24. Windyga J., Rozpoznanie i leczenie zakrzepowej plamicy maloplytkowej. Omówienie wytycznych International Society on Thrombosis and Haemostasis, Med. Prakt., 2021; 12: 60-68
  25. James P.D., Connell N.T., Ameer B. y cols., ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand disease, Blood Adv., 2021; 5: 280-300
  26. Connell N.T., Flood V.H., Brignardello-Petersen R. y cols., ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease, Blood Adv., 2021; 5: 301-325
  27. Shui M., D’Angelo L., Croteau S.E., Diagnostic and therapeutic decision making in pediatric patients with low von Willebrand factor, Blood, 2019; doi: 10.1182/blood-2019-123 734
  28. Bowman M.L., James P.D., Controversies in the diagnosis of type 1 von Willebrand disease, Int. Jnl. Lab. Hem., 2017; 39 (supl. 1): 61-68
  29. Flood V.H., Gill J.C., Friedman K.D. y cols., Collagen binding provides a sensitive screen for variant von Willebrand disease, Clin. Chem., 2013, 59: 684-691
  30. Windyga J., Emicizumab in severe hemophilia A, Acta Haematol. Pol., 2021; 52: 422-428
  31. Callaghan M.U., Negrier C., Paz-Priel I. y cols., Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1–4 studies, Blood, 2021, 137: 2231-2242
  32. Oldenburg J., Mahlangu J.N., Kim B. y cols., Emicizumab prophylaxis in hemophilia A with inhibitors, N. Engl. J. Med., 2017; 377: 809-818
  33. Hart D.P., Alamelu J., Bhatnagar N. y cols., Immune tolerance induction in severe haemophilia A: A UKHCDO inhibitor and paediatric working party consensus update, Haemophilia, 2021; 27: 932-937
  34. Klamroth R., Windyga J., Radulescu V. y cols., Rurioctocog alfa pegol PK-guided prophylaxis in hemophilia A: results from the phase 3 PROPEL study, Blood, 2021, 137: 1818-1827
  35. Windyga J., Profilaktyka i leczenie zylnej choroby zakrzepowo-zatorowej u chorych na nowotwór zlosliwy. Omówienie wytycznych American Society of Hematology 2021, Med. Prakt., 2021; 7-8: 8-15
  36. Lee J.W., Sicre de Fontbrune F., Wong Lee L. y cols., Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study, Blood, 2019, 133: 530-539
  37. Kulasekararaj A.G., Hill A., Rottinghaus S.T. y cols., Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: the 302 study, Blood, 2019, 133: 540-549
  38. Hillmen P., Szer J., Weitz I. y cols., Pegcetacoplan versus eculizumab in paroxysmal nocturnal hemoglobinuria, N. Engl. J. Med., 2021; 384: 1028-1037
  39. Kulasekararaj A.G., Risitano A.M., Maciejewski J.P. y cols., Phase 2 study of danicopan in patients with paroxysmal nocturnal hemoglobinuria with an inadequate response to eculizumab, Blood, 2021, 138: 1928-1938

Volver al artículo principal: Alteraciones de la hemostasia: avances de 2021/2022

Siguiente artículo: Guías de manejo de la enfermedad de Von Willebrand